Filing Details

Accession Number:
0000939767-21-000038
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-31 21:02:49
Reporting Period:
2021-03-29
Accepted Time:
2021-03-31 21:02:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
939767 Exelixis Inc. EXEL Biological Products, (No Disgnostic Substances) (2836) 043257395
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1023225 L Jack Wyszomierski C/O Exelixis, Inc.
1851 Harbor Bay Parkway
Alameda CA 94502
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-29 40,000 $3.38 237,809 No 4 M Direct
Common Stock Disposition 2021-03-29 6,220 $22.64 231,589 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option (right to buy) Disposition 2021-03-29 40,000 $0.00 40,000 $3.38
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-05-29 2021-05-28 No 4 M Direct
Footnotes
  1. Includes 7,728 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
  2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2021.
  3. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.91. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
  4. The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014.